Stockwinners Market Radar for May 23, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Virgin Galactic (SPCE) has completed its third spaceflight and the first ever spaceflight from Spaceport America, New Mexico. The flight sees New Mexico become the third U.S. state to launch humans into space. VSS Unity achieved a speed of Mach 3 after being released from the mothership, VMS Eve, and reached space, at an altitude of 55.45 miles before gliding smoothly to a runway landing at Spaceport America. 2. The U.S. and Europe reacted with outrage after Belarus ordered a Ryanair (RYAAY) flight transiting its airspace to land and arrested a journalist on board, an unprecedented violation of European air travel protocols, Bloomberg's Milda Seputyte and Aliaksandr Kudrytski reported. Europe's fury was triggered after a Boeing (BA) 737-800 carrying scores of passengers from Athens to Vilnius was diverted to the Belarusian capital on Sunday under the escort of a Mig-29 fighter jet, the authors noted. The plane's crew was notified by authorities in Minsk of a "potential security threat on board," a Ryanair spokeswoman said. Once in Minsk, authorities arrested a journalist who covered protests against President Alexander Lukashenko, whose election to a sixth term last year was internationally disputed. 3. AT&T set out to announce a transformative deal this past week, but the company's shareholders got stuck on the fine print disclosed in the news, namely that AT&T was slashing its dividend, Nicholas Jasinski wrote in this week's edition of Barron's. The spinoff of WarnerMedia-and its subsequent combination with Discovery (DISCA)-is a vital course correction for AT&T (T) as it seeks to regain its telecom leadership, the author noted. The issue for investors is that AT&T's fundamentals have long played second fiddle to the company's generous dividend, he added. AT&T's stock has traded at an annual dividend yield of close to 7% for most of the past year, and about 5% for several years before that, which is a generous payout in a world of rock-bottom interest rates and paltry bond yields, and it attracted numerous income investors and retirees who rely on the quarterly payouts, according to Jasinski, who said it is time to buy AT&T stock. 4. Lionsgate's (LGF.A) "Spiral: From the Book of Saw" won the weekend at the North American box office, with an $8.7M debut from 2,811 locations. Marking a new chapter in the Saw franchise with new characters, Spiral stars Chris Rock, Max Minghella, Marisol Nichols and Samuel L. Jackson. Roughly 45% of cinemas remain dark in North America as reopening continues. 5. Cisco (CSCO) and Kohl's (KSS) saw positive mentions in this week's edition of Barron's.

16:11 EDT InspirMed presents data on ISPM21, ISPM19 at ISAM Congress - InspirMed, a subsidiary of TLC, presents data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 - named ISPM21 - and inhalable liposomal hydroxychloroquine - named ISPM19 - showed higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis and/or treatment for COVID-19. GS-441524 is main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the U.S. for the treatment of COVID-19. The company notes that administration of remdesivir requires cyclodextrin, "a complex excipient cleared by the kidneys and associated with nephrotoxicity," while in comparison, GS-441524 "demonstrated similar or superior potency to remdesivir in SARS-CoV-2-infected cells, is bioactivated by enzymes that are highly expressed in AT1/2 cells, and demonstrated an excellent safety profile against human liver and kidney cells in vitro, suggesting feasibility of higher dosing without hepatotoxicity or nephrotoxicity."

08:34 EDT Takeda announces long-term safety, efficacy results for dengue vaccine candidate - Takeda Pharmaceutical announced that its dengue vaccine candidate demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study trial. TIDES enrolled more than 20,000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia. Safety and efficacy results from the 36-month follow-up exploratory analysis of TIDES were presented on May 22, 2021, at the 17th Conference of the International Society of Travel Medicine. Through three years, TAK-003 demonstrated overall vaccine efficacy of 62.0% against virologically-confirmed dengue, with 65.0% VE in seropositive individuals and 54.3% VE in seronegative individuals. TAK-003 also demonstrated 83.6% VE against hospitalized dengue, with 86.0% VE in seropositive individuals and 77.1% VE in seronegative individuals. Observations of varied VE by serotype remained consistent with previously reported results. No evidence of disease enhancement was observed. TAK-003 was generally well tolerated, and there were no important safety risks observed. The results reinforce the potential of TAK-003 to help protect those who are living in or traveling to dengue-endemic countries, the company added.